Isaksson, S. http://orcid.org/0000-0001-8935-8479
Bogefors, K.
Åkesson, K.
Øra, I.
Egund, L.
Bobjer, J.
Leijonhufvud, I.
Giwercman, A. http://orcid.org/0000-0001-5816-0785
Funding for this research was provided by:
Swedish Cancer Society (CAN 2012/661)
Swedish Childhood Cancer Society (PROJ12/049)
Malmö University Hospital Cancer Fund (-)
Skane University Hospital Fund (-)
Swedish governmental funding for clinical research (-)
Region Scania Research Fund (-)
Article History
Received: 27 February 2019
Accepted: 6 January 2020
First Online: 1 February 2020
Compliance with ethical standards
: All participants signed an informed consent form, and the Regional Ethics Committee, Lund University, approved the study.
: Aleksander Giwercman has, more than 2 years ago, been paid for a consulting role by Bayer, and for providing expert testimony on behalf of Ferring Pharmaceuticals. During the last 2 years, Aleksander Giwercman has conducted research projects—not related to current study—funded in part by Ferring Pharmaceuticals. Kristina Åkesson has received lecture or temporary consultancy fees from Amgen, UCB, Eli Lilly, Merck and Sandoz, none related to this study. Ingrid Øra is since 2018 member as consultant in Bayer advisory board.